BIO Stock Analysis: Buy, Sell, or Hold?
BIO - Bio-Rad Laboratories, Inc.Class A
$293.70
-1.21 (-0.41%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
11d
Get Alerted When BIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called BIO this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BIO shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: BIO shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$294.08
Based on 3.0% avg growth
INTRINSIC VALUE TODAY
$182.60
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIO is currently trading at $293.70, which is considered oversold relative to its 30-day fair value range of $299.07 to $319.94. The stock's valuation (Forward PE: 29.1) is in line with its historical norms (30.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BIO is in a uptrend. The price is currently testing key support at $287.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $348.00 (+18.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIO is in a uptrend. The price is currently testing key support at $287.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $348.00 (+18.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$299.07 -
$319.94
Company Quality Score
53/100
(HOLD)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 36th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($348.00)
Fair Price Analysis
30-Day Fair Range
$299.07 -
$319.94
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$20.42
(7.0%)
Support & Resistance Levels
Support Level
$287.46
Resistance Level
$322.82
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
29.06
Wall Street Target
$348.00
(+18.0%)
Revenue Growth (YoY)
0.5%
Earnings Growth (YoY)
-83.0%
Profit Margin
-26.4%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
29.1 vs 30.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$290.78
(-1%)
2-Year Target
$286.71
(-3%)
3-Year Target
$282.70
(-4%)
3-Yr Target (if PE normalizes)
(PE: 29→30)
$294.76
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.1, Growth: 2.0%)
$312.58
(+6%)
Base:
(SPY PE: 22.3, Growth: 2.0%)
$239.87
(-19%)
Bear:
(PE: 19.0, Growth: 2.0%)
$203.89
(-31%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 29.1 to 30.3
Stabilization Target:
$307.50
(+4.3%)
PE Expansion Potential:
+4.3%
Last updated: January 31, 2026 9:43 AM ET
Data refreshes hourly during market hours. Next update: 10:43 AM
Data refreshes hourly during market hours. Next update: 10:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$427 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$110 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
Advanced BIO Option Strategies
Professional options setups generated by AI based on today's BIO price and gamma walls.
